Misoprostol in the treatment of trigeminal neuralgia associated with multiple sclerosis.
Multiple sclerosis can be associated with trigeminal neuralgia which is often difficult to treat in this specific condition. We performed an open prospective trial on the efficacy and safety of the prostaglandin-E1-analogue misoprostol (600 microg per day) in the reduction of attack frequency and pain intensity in patients with refractory trigeminal neuralgia associated with multiple sclerosis. Eighteen patients completed the study period and 14 of them showed a reduction of more than 50 % in attack frequency and intensity beginning five days after treatment onset. There were only mild and transient drug related side effects in three patients. One patient stopped taking misoprostol after the study period because of severe menorrhagia. Our results suggest that misoprostol is effective and safe in the treatment of this specific type of refractory trigeminal neuralgia.
D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D016595:Misoprostol / Q000627:therapeutic use*; D009103:Multiple Sclerosis / Q000150:complications* / Q000188:drug therapy* / Q000503:physiopathology; D011446:Prospective Studies; D014277:Trigeminal Neuralgia / Q000150:complications* / Q000188:drug therapy* / Q000503:physiopathology
D016595:Misoprostol